In keeping with the pivotal role exerted by the FGF/FGFR system in MM growth and progression, clinical trials are in progress to assess the effect of FGF signaling blockade by selective FGFR TK inhibitors in relapse/refractory MM patients (ClinicalTrials.gov). The gene discussed is TKT; the disease is Miyoshi myopathy.